Search Results

IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced that Damon Burrows, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:30 a.m. ET.

IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. Richard L. Abbott and Dr. Lixin Xie.

IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. (“TALLC”), a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, today announced that they are entering into a strategic collaboration and licensing agreement.

IACTA Pharmaceuticals, Inc. (IACTA), an innovation leader in ophthalmic therapeutics, today announced the appointment of Yogesh Bahl as Chief Financial Officer (CFO) and Eric Carter, M.D., Ph.D., as Chief Medical Officer (CMO).

IACTA Pharmaceuticals, Inc. today announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.